SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel solid tumor ablation therapy, announced today that the Journal of Virology has published a scientific paper prepared by Inovio’s development partner, Wyeth, regarding results from a non-human primate study of an investigational DNA vaccine against HIV delivered using Inovio Biomedical’s electroporation technology. The paper, titled “Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques,” summarized results of a research project lead by Michael A. Egan, Ph.D., a principle research scientist at Wyeth Vaccine Research. The scientific paper concluded: “These results indicate that in vivo electroporation appears safe and can dramatically improve the delivery and immunogenicity of a multi-vector, multi-antigen pDNA vaccine in non-human primates. Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection.”
